{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T02:43:07Z","timestamp":1768444987911,"version":"3.49.0"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":4390,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2001,3]]},"abstract":"<jats:p>The objective of this study was to investigate the influence of food on the pharmacokinetics of tolterodine, its active 5\u2010hydroxymethyl metabolite (5\u2010HM), and exposure to the active moiety (sum of unbound tolterodine + 5\u2010HM) in healthy volunteers. Serum concentrations of tolterodine and 5\u2010HM were measured for up to 12 hours after a single oral dose (2 mg) of tolterodine L\u2010tartrate, administered either on an empty stomach or with a standardized medium\u2010fat breakfast. All 23 subjects completing the study were classified as extensive metabolizers (phenotyped with debrisoquine). Pharmacokinetic data on tolterodine and the active moiety were evaluable for 22 subjects; all completing subjects were evaluable for 5\u2010HM pharmacokinetics. Based on C<jats:sub>max<\/jats:sub> and AUC\u221e ratios, relative bioavailability of tolterodine in the presence of food was 1.49 (90% confidence interval [CI], 1.35\u20101.71) and 1.53 (1.35\u20101.72), respectively. The pharmacokinetics of 5\u2010HM and the active moiety were unaffected by food, as were the rates of drug absorption and terminal half\u2010lives of tolterodine and 5\u2010HM. Given that bioequivalence was observed for the active moiety underfed and fasting conditions, the authors concluded that coadministration of tolterodine with food is not expected to have any clinically relevant effects.<\/jats:p>","DOI":"10.1177\/00912700122010113","type":"journal-article","created":{"date-parts":[[2003,7,19]],"date-time":"2003-07-19T09:38:13Z","timestamp":1058607493000},"page":"298-304","source":"Crossref","is-referenced-by-count":15,"title":["Food Increases the Bioavailability of Tolterodine but Not Effective Exposure"],"prefix":"10.1002","volume":"41","author":[{"given":"Birgitta","family":"Olsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niclas","family":"Brynne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Arnberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"56","article-title":"The overactive bladder: an overview for primary care health providers","volume":"44","author":"Wein AJ","year":"1999","journal-title":"Int J Fertil"},{"key":"e_1_2_1_3_2","volume-title":"Physicians' Desk Reference.","year":"2000"},{"key":"e_1_2_1_4_2","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity","volume":"35","author":"Brynne N","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1023\/A:1012095115151","article-title":"Intestinal permeability of tolterodine, a new muscarinic receptor antagonist (abstract 1078)","volume":"14","author":"Schipper NGM","year":"1997","journal-title":"Pharm Res"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90104-7"},{"key":"e_1_2_1_7_2","first-page":"289","article-title":"Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes","volume":"26","author":"Postlind H","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1997.tb02064.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91430-1"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316090"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1999.00053.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-081X(199903)20:2<91::AID-BDD162>3.0.CO;2-Y"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(98)00629-3"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198409050-00002"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199325040-00005"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9673(00)89216-X"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(97)00023-X"},{"key":"e_1_2_1_18_2","volume-title":"Clinical Pharmacokinetics: Concepts and Applications.","author":"Rowland M","year":"1995"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197407010-00003"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1987.tb03109.x"},{"issue":"3","key":"e_1_2_1_21_2","first-page":"64","article-title":"Polymorphic oxidative metabolism of propafenone in man (abstract)","volume":"68","author":"Siddoway LA","year":"1983","journal-title":"Circulation"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.94"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1977221108"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02336686"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.135"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cpt19782415","article-title":"Food, splanchnic blood flow, and bioavailability of drugs subject to first\u2010pass metabolism","volume":"24","author":"MacLean A","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1986.198"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1983.174"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510110107"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198308040-00002"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F00912700122010113","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/00912700122010113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T14:41:54Z","timestamp":1700404914000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/00912700122010113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2001,3]]}},"alternative-id":["10.1177\/00912700122010113"],"URL":"https:\/\/doi.org\/10.1177\/00912700122010113","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,3]]}}}